The present disclosure relates to salts of the compound (I) polymorphic forms thereof methods for preparation and use thereof and pharmaceutical compositions thereof.
Novel attenuating deletions of Chikungunya virus E2 polypeptides are provided as are attenuated viruses comprising the deletions. Also provided are immunogenic compositions comprising the attenuated viruses and methods of producing such viruses in cells (such as insect cells). Viruses of the embodiments can be used ...
Methods and compositions concerning mutant flaviviruses with host range mutations. In some embodiments the invention concerns nucleotide sequences that encode mutant flavivirus proteins. Viruses comprising these sequences that display reduced replication in mammalian cells are provided. In further aspects of the inv...
The present invention regards targeted BLyS polypeptides capable of binding to BLyS receptors and that deliver a cytotoxic agent, such as a cytotoxic peptide, for example. In particular aspects, the cytotoxic agent comprises at least part of rGelonin. These compositions are useful for treating, preventing, and/...
The present invention concerns chimeric cancer therapeutic molecules comprising a targeting rnoiety and an anti-cell proliferation moiety. The anti-cell proliferation moiety may comprise a cytotoxic agent or an apoptosis-inducing factor, in specific embodiments. In particular embodiments, the anti-cell proliferation...
Documents
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-07112020
Directors report as per section 134(3)-07112020
Optional Attachment-(1)-07112020
Form AOC-4-07112020_signed
Form BEN - 2-13102020_signed
Declaration under section 90-13102020
List of share holders, debenture holders;-22092020
Form MGT-7-22092020_signed
Form MGT-7-11032019_signed
Form AOC-4-11032019_signed
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-05032019
Directors report as per section 134(3)-05032019
List of share holders, debenture holders;-05032019
Directors report as per section 134(3)-26112017
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-26112017
List of share holders, debenture holders;-26112017
Form AOC-4-26112017_signed
Form MGT-7-26112017_signed
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-19012017
Directors report as per section 134(3)-19012017
Form AOC-4-19012017_signed
Form MGT-7-05122016_signed
Optional Attachment-(1)-29112016
List of share holders, debenture holders;-29112016